Phibro Animal Health announced a Brazilian regulatory prohibition on certain antimicrobial feed additives, effective after a 180-day transition period, with limited fiscal 2026 impact expected.
Key takeaways
Brazil's MAPA published Ordinance No. 1617 prohibiting performance-enhancing antimicrobials including virginiamycin and bacitracin.
The prohibition becomes effective after a 180-day transition period, allowing continued sales under current labels.
The Company expects the regulatory change to have limited impact on fiscal year 2026 results.
Phibro is pursuing new therapeutic registrations for virginiamycin and already holds therapeutic claims for bacitracin.
The Company launched PhibroVet®, a digital platform to manage veterinary prescriptions required under the new framework.